Data Monitoring Committees and clinical trials: from scientific justification to organisation - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Therapies Année : 2024

Data Monitoring Committees and clinical trials: from scientific justification to organisation

Peggy Derambure
  • Fonction : Auteur
Alix Avakiantz
  • Fonction : Auteur
Claire Bahans
  • Fonction : Auteur
Pierre Fustier
  • Fonction : Auteur
Cecile Train
  • Fonction : Auteur
Michel Cucherat

Résumé

Clinical trials often last several months or even several years. As the trial progresses, it can be tempting to find out whether the data obtained already answers the question posed at the start of the trial in order to stop inclusions or monitoring earlier. However, knowing and taking into account interim results can sometimes compromise the integrity of the results, which is counterproductive. To minimise this risk and ensure that the treatments are assessed reliably, safety and/or efficacy criteria are monitored during the study by a Data Monitoring Committee. After receiving the results confidentially, the Data Monitoring Committee assesses the benefit/risk ratio of the study treatment and recommends that the trial be continued, modified or terminated. Data Monitoring Committee members issuing these recommendations have an important responsibility: a hasty decision to end the trial may lead to inconclusive results unable to answer the initial question and, inversely, delaying the decision to end the trial may expose the subjects to potentially ineffective or even harmful interventions. The Data Monitoring Committee's task is therefore particularly complex. With this in mind, the round table discussion at the Giens workshops was a chance to review the scientific justification for creating Data Monitoring Committees and to recall the need for their members to receive comprehensive training on the complexities of multiple analyses, confidentiality requirements applying to the results and the need for them to be aware that recommendations to end a trial must be based on data that is robust enough to assess the benefit/risk ratio of the treatment studied.
Fichier sous embargo
Fichier sous embargo
0 1 5
Année Mois Jours
Avant la publication
mercredi 5 juin 2024
Fichier sous embargo
mercredi 5 juin 2024
Connectez-vous pour demander l'accès au fichier

Dates et versions

hal-04350974 , version 1 (25-04-2024)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Clara Locher, Silvy Laporte, Peggy Derambure, Olivier Chassany, Cécile Girault, et al.. Data Monitoring Committees and clinical trials: from scientific justification to organisation. Therapies, 2024, 79 (1), pp.111-121. ⟨10.1016/j.therap.2023.12.002⟩. ⟨hal-04350974⟩
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More